A large laboratory study found that many commonly used sweeteners can directly change the growth of gut bacteria. Researchers identified more than 100 cases in which sweeteners behaved differently when combined with medications, caffeine, or flavorings. The combination of isosteviol and the antidepressant duloxetine was especially disruptive, reducing beneficial bacteria and overall microbial diversity.

A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.

A new experimental treatment may have found a way to outsmart glioblastoma’s toughest defense: the blood-brain barrier. Researchers used sugar-coated nanoparticles to ferry genetic instructions that restore a key tumor-suppressing protein directly into brain cancer cells. In mouse studies, the therapy increased median survival by 50% while shrinking tumors without noticeable damage to other organs.

An international study found that finerenone slows kidney function decline and reduces the risk of serious kidney and cardiovascular complications in people with chronic kidney disease who do not have diabetes. The results could open the door to a much-needed new treatment option for the majority of CKD patients who have long had limited choices.

Researchers solved a long-standing mystery behind how a bacterial toxin associated with colorectal cancer damages the colon. The toxin first binds to a receptor called claudin-4, giving it access to attack the cells' protective barrier. After identifying this weak point, the team designed a decoy protein that successfully blocked the toxin in mice. The discovery could pave the way for new therapies to prevent inflammation and colon tumors.